Sugi Predict

Sugi Predict / Compounds / SCHEMBL15076397

SCHEMBL15076397

SCHEMBL15076397

O=C(Nc1cc(F)c(F)c(F)c1)c1ccc(Cl)c(S(=O)(=O)N2CCC(CCO)CC2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.55
▸ TP53 P04637 5/20 0.55
▸ LMNA P02545 6/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ ENPP2 Q13822 2/20 0.50
▸ LPAR1 Q92633 1/20 0.50
▸ SMN1; SMN2 Q16637 5/20 0.49
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ POLB P06746 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ CNR2 P34972 1/20 0.49
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ KCNH2 Q12809 1/20 0.48
▸ USP2 O75604 1/20 0.48
▸ MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15076398 0.96 MAPT (0.53) MAPTTP53LMNARAB9AENPP2
SCHEMBL15076713 0.92 MAPT (0.60) MAPTTP53LMNARAB9ASMN1; SMN2
SCHEMBL19157110 0.90 MAPT (0.52) MAPTTP53LMNARAB9AENPP2
SCHEMBL15076401 0.89 MAPT (0.54) MAPTTP53LMNARAB9ASMN1; SMN2
SCHEMBL19324776 0.88 MAPT (0.48) MAPTTP53LMNARAB9AENPP2
SCHEMBL15076488 0.88 CYP3A4 (0.62) MAPTTP53LMNARAB9AENPP2
SCHEMBL15277032 0.87 MAPT (0.56) MAPTTP53LMNARAB9ASMN1; SMN2
SCHEMBL15076495 0.85 CYP1A2 (0.56) MAPTTP53LMNARAB9AENPP2
SCHEMBL15076768 0.84 MAPT (0.60) MAPTTP53LMNARAB9ASMN1; SMN2
SCHEMBL15076476 0.84 CYP3A4 (0.57) MAPTTP53LMNARAB9AENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020255012-A1 COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING SULFONAMIDE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2020-12-24 — — WO disclosed
US-10632112-B2 Combination therapy for treatment of HBV infections NOVIRA THERAPEUTICS, INC. (US) 2020-04-28 — — US disclosed
US-20190209541-A1 COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS NOVIRA THERAPEUTICS INC. 2019-07-11 — — US disclosed
US-10196376-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2019-02-05 — — US disclosed
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC 2017-11-23 — — US disclosed
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC 2017-11-23 — — US disclosed
US-9751857-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2017-09-05 — — US disclosed
US-9751857-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2017-09-05 — — US disclosed
EP-2794565-B1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS INC (US) 2017-07-26 — — EP disclosed
US-20170182021-A1 COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS NOVIRA THERAPEUTICS, INC. 2017-06-29 — — US disclosed
US-9061008-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2015-06-23 — — US disclosed
US-20150152073-A1 Hepatitis B Antiviral Agents NOVIRA THERAPEUTICS, INC. 2015-06-04 — — US disclosed
US-20150152073-A1 Hepatitis B Antiviral Agents NOVIRA THERAPEUTICS, INC. 2015-06-04 — — US disclosed
US-20140178337-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2014-06-26 — — US disclosed
US-20140178337-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2014-06-26 — — US disclosed
US-8629274-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2014-01-14 — — US disclosed
US-8629274-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2014-01-14 — — US disclosed
US-20130251673-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. (US) 2013-09-26 — — US disclosed
US-20130251673-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. (US) 2013-09-26 — — US disclosed
WO-2013096744-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. (US) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10632112-B2 Combination therapy for treatment of HBV infections IFNAR1, IFNG, HDGF MAPT 3999/4885TP53 920/4885LMNA 1365/4885
US-20150152073-A1 Hepatitis B Antiviral Agents HAVCR2, EIF2AK2, IRF3 MAPT 4607/4885TP53 1486/4885LMNA 3521/4885
US-20140178337-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 MAPT 4607/4885TP53 1486/4885LMNA 3521/4885
US-10196376-B2 Hepatitis B antiviral agents HAVCR2, EIF2AK2, IRF3 MAPT 4607/4885TP53 1486/4885LMNA 3521/4885
US-20190209541-A1 COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS IFNAR1, IFNG, HDGF MAPT 3999/4885TP53 920/4885LMNA 1365/4885
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 MAPT 4607/4885TP53 1486/4885LMNA 3521/4885
US-20130251673-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 MAPT 4607/4885TP53 1486/4885LMNA 3521/4885
US-20170182021-A1 COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS IFNAR1, IFNG, HDGF MAPT 3999/4885TP53 920/4885LMNA 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.